RxDoctor Payments Data

Amal El-Bakush, MD

Critical Care Medicine · Cedar Rapids, IANPI 1609162908

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (48.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 72.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2023 at $11,437 and has fallen 93.5% since, to $744 in 2025. Among critical care medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,829in general payments, 2019–2025

Across 279 payments — averaging $67.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$14K
  • AstraZeneca$1K
  • Boehringer Ingelheim$709
  • United Therapeutics Corporation$559
  • GSK$526
  • AbbVie$350
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$4,25423%
  • Food & beverage$5,50429%
  • Education$9,07148%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,829 in reported general payments places this provider in the 95th percentile of 33 critical care medicine providers in Iowa.

See all critical care medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$59,713
Medicare patients
368
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter464$329,205
Breo ElliptaFluticasone/Vilanterol279$116,286
Breztri AerosphereBudesonide/Glycopyr/Formoterol161$108,599
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr187$97,040
Dupixent SyringeDupilumab11$41,468
Stiolto RespimatTiotropium Br/Olodaterol Hcl52$27,160
SymbicortBudesonide/Formoterol Fumarate76$20,522
Spiriva RespimatTiotropium Bromide30$18,400
Advair HfaFluticasone Propion/Salmeterol35$14,280
Bevespi AerosphereGlycopyrrolate/Formoterol Fum27$11,200
Incruse ElliptaUmeclidinium Bromide25$10,450
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$10,021
Albuterol Sulfate HfaAlbuterol Sulfate267$6,975
Fluticasone-SalmeterolFluticasone Propion/Salmeterol65$5,945
Arnuity ElliptaFluticasone Furoate20$5,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$526$558,086975 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,295$140,321264 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$709$45,56182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 critical care medicine providers in Iowa.

Other critical care medicine in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →